{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-015648","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.710270+00:00","generated_at":"2026-05-27T07:10:15.924941+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused","bullets":["Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.","No improvement on primary efficacy measure MDS-UPDRS Parts 2+3 at any dose vs placebo.","Secondary signals: Part 2 improved -1.41 at 100 mg (p=0.036); Schwab & England +4% at 50 mg (p=0.0004).","Skin biopsy analysis suggests treatment-dependent reduction in neuronal alpha-synuclein deposition.","Company pausing risvodetinib to focus resources on IkT-001Pro for PAH; evaluating strategic options."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-015648","json":"https://secwatch.observer/filing/0001193125-25-015648.json","markdown":"https://secwatch.observer/filing/0001193125-25-015648.md","text":"https://secwatch.observer/filing/0001193125-25-015648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525015648/0001193125-25-015648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525015648/d919757d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:10:15.924941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}